PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Dolomite Microfluidics

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Dolomite and Clearbridge BioMedics Develop Revolutionary Instrument for Cancer Detection - Microfluidics expert, Dolomite announces collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood
Dolomite and Clearbridge BioMedics Develop Revolutionary Instrument for Cancer Detection

 

NewswireToday - /newswire/ - Royston, Herts, United Kingdom, 2011/11/23 - Microfluidics expert, Dolomite announces collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Microfluidics expert, Dolomite, is delighted to announce its collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.

The innovative ClearCell™ System can isolate, enumerate and most importantly retrieve wholly intact and viable CTCs from patient whole blood. Benefiting a broad range of application areas including molecule analysis, cancer diagnostics and cancer treatment decisions, this revolutionary instrument also paves the way for personalised cancer medication for patients.

Speaking of this success, Andrew Lovatt, the CEO of Dolomite, says,“We are excited to be working with an innovative company like Clearbridge BioMedics. The collaboration is an excellent example of how Dolomite is able to help start-up companies productize science. By combining the cutting edge scientific research of Clearbridge BioMedics and National University of Singapore with the proven track record in product development of Dolomite, both companies have leveraged their expertise to gain early traction in the novel field of automated capture of viable CTCs. We are looking forward to extending our partnership beyond research tools and into the clinical diagnostic domain."

“We see microfluidics playing an increasing key role in many Companion Diagnostics and In-Vitro Diagnostics devices. Dolomite has demonstrated that they are indeed a leader in this field, and we look forward to developing our future platform devices and systems together“, commented Johnson Chen, Managing Director of Clearbridge BioMedics.

For further information on Dolomite’s instrument development solutions as well as the complete portfolio of microfluidic products including chips, connectors/ interconnects, pumps, valves and custom devices please visit dolomite-microfluidics.com/.

About The Dolomite Centre Limited
Established in 2005 as the world’s first Microfluidic Application Centre, Dolomite focused on working with customers to turn their concepts for microfluidic applications into reality. Today, Dolomite is the world leader in solving microfluidic problems. With offices in the UK and US and distributors throughout the rest of the world, its clients range from universities developing leading-edge analytical equipment, to manufacturers of chemical, life sciences and clinical diagnostics systems.

Dolomite (dolomite-microfluidics.com) is pioneering the use of microfluidic devices for small-scale fluid control and analysis, enabling manufacturers to develop more compact, cost-effective and powerful instruments. By combining specialist glass, quartz and ceramic technologies with knowledge of high performance microfluidics, Dolomite is able to provide solutions for a broad range of application areas including environmental monitoring, clinical diagnostics, food and beverage, nuclear, agriculture, petrochemical, cosmetics, pharmaceuticals and chemicals. Furthermore Dolomite's in-house micro-fabrication facilities that include clean rooms and precision glass processing facilities allow to prototype and test all solutions rapidly which ensures a faster development cycle and reduces the time to market.

About Clearbridge BioMedics
Clearbridge BioMedics is a spin-off from the National University of Singapore (NUS), and an incubatee of Clearbridge Accelerator, a Singapore Government backed high-technology incubator. Leveraging on a microfluidic biochip invention, its ClearCell™ System comprises patent-pending microfluidic CTChips®, which are able to effectively detect and isolate wholly-intact CTCs (Circulating Tumour Cells) from small quantities of whole patient blood samples.

Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.

For more information on Clearbridge BioMedics’ ClearCell™ System and CTChip®, please visit ClearbridgeBioMedics.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Dolomite Microfluidics

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Dolomite and Clearbridge BioMedics Develop Revolutionary Instrument for Cancer Detection

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Marketing - Dolomite-Microfluidics.com 
+44(0)17 6324 2491 marketing[.]dolomite-microfluidics.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Dolomite Microfluidics securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Dolomite Microfluidics / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)